You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)

Article metrics

Article menu

Download PDFPDF

E-Poster viewings
Ovarian Cancer
IGCS19-0435
312 Aries: a phase 2, open-label study to evaluate rucaparib (PARP inhibitor) in combination with nivolumab (Anti-PD-1 Antibody) in patients with ovarian or urothelial cancer (UC)
Free

 

Online download statistics by month:

Online download statistics by month: September 2019 to April 2024

AbstractFullPdf
Sep 201916010
Oct 20193107
Nov 2019809
Dec 20191205
Jan 20201603
Feb 2020404
Mar 2020802
Apr 20201404
May 20201604
Jun 20201606
Jul 20201904
Aug 20202203
Sep 20202201
Oct 20201602
Nov 2020800
Dec 20202600
Jan 20211704
Feb 20211001
Mar 20214607
Apr 20211606
May 2021404
Jun 2021002
Jul 2021004
Aug 2021003
Sep 2021003
Oct 202110021
Nov 202130012
Dec 20213402
Jan 20224000
Feb 20223401
Mar 20222201
Apr 20221601
May 202230012
Jun 20221602
Jul 20223102
Aug 202218014
Sep 20223109
Oct 20221303
Nov 20222207
Dec 20222301
Jan 2023804
Feb 20232601
Mar 20231802
Apr 20232604
May 20231204
Jun 2023802
Jul 20231403
Aug 20231408
Sep 20237010
Oct 20232908
Nov 20231802
Dec 20231902
Jan 2024400
Feb 2024604
Mar 202413078
Apr 2024709
Total9460327